Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
03 déc. 2020 06h01 HE
|
Immunocore Limited
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
Immunocore Secures $130 Million Series B Financing
02 mars 2020 07h00 HE
|
Immunocore Limited
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
Immunocore strengthens IP position in the field of TCR-based therapeutics
05 sept. 2018 07h00 HE
|
Immunocore Limited
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore strengthens IP position in the field of TCR-based therapeutics
05 sept. 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
20 août 2018 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
20 août 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...